Roivant Sciences Ltd. (ROIV) Stock

Roivant Sciences Ltd. (ROIV) is a Healthcare stock trading at $31.40 (as of 2026-06-18), with a market capitalization of $21.57B and a trailing P/E of -55.5. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.

Valuation — source: SEC EDGAR (first-party)
Price	$31.40
Market Cap	$21.57B
P/E Ratio	-55.5
EV / EBITDA	-39.4
Price / Book	4.08
Price / Sales	2611.49
DCF Value (model)	$-15.96
DCF Upside vs Price	-150.8%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$8.26M
Net Margin	-3629.2%
Return on Equity	-5.7%
Current Ratio	18.37
Revenue Growth (YoY)	-71.6%
EPS Growth (YoY)	79.2%
FCF Growth (YoY)	-10.1%

Financial Health — source: SEC EDGAR
Altman Z-Score	33.16 (safe)

Valuation vs Sector & Industry
Stock P/E	-55.5
Sector P/E (Healthcare)	21.0
Industry P/E (Pharmaceutical Products)	17.3
vs Sector	-365.0%
vs Industry	-421.7%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	FMR LLC ($2.16B)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Matthew Gline
Employees	908
Country	GB
IPO Date	2020-12-08

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.